^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Intron A (interferon α-2b)

    i
    Other names: SCH 30500, YM 14090
    Company:
    Biogen, Merck (MSD)
    Drug class:
    IFNα 2b stimulant
    Related drugs:
    3d
    Decoding the SHOX2 Methylation-Expression Paradox in Lung Adenocarcinoma: Dual-Regulatory Methylation Patterns Drive Oncogenic Activation and Prognostic Relevance. (PubMed, Cancer Lett)
    Our findings redefine epigenetic regulation in LUAD, demonstrating that regional methylation patterns-not global promoter status-orchestrate oncogene activation. We propose a novel framework for spatially resolved methylomics, advocating 1) dual-target assays monitoring both promoter and gene body methylation to improve diagnostic precision, and 2) therapeutic exploitation of SHOX2's intronic methylome as a druggable epigenetic switch.
    Journal
    |
    SHOX2 (SHOX Homeobox 2)
    |
    Epi proLung®
    |
    Intron A (interferon α-2b)
    1m
    SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov)
    P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Mycapssa (octreotide) • Avzivi (bevacizumab-tnjn) • Intron A (interferon α-2b) • Bioferon (interferon alpha 2b) • octreotide acetate
    1m
    SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1301, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Intron A (interferon α-2b) • Bioferon (interferon alpha 2b)
    1m
    High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma (clinicaltrials.gov)
    P3, N=1150, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Intron A (interferon α-2b)
    2ms
    Study on the Impact and Safety of Vaginal Lactobacillus Viable Capsules on the Clearance Rate of High‑Risk HPV Infection in Postmenopausal Women (ChiCTR2500114563)
    P4, N=222, Not yet recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
    New P4 trial
    |
    Intron A (interferon α-2b)
    3ms
    Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov)
    P1/2, N=4, Terminated, Roswell Park Cancer Institute | N=64 --> 4 | Suspended --> Terminated; Low accrual
    Enrollment change • Trial termination
    |
    CCL22 (C-C Motif Chemokine Ligand 22)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod)
    3ms
    Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance). (PubMed, Cancer Immunol Res)
    Combination therapy was reasonably well-tolerated but conferred marginal benefit in patients with metastatic melanoma. These results can inform future studies that employ recombinant IL-12 or novel IL-12 constructs.
    P2 data • Journal
    |
    IFNG (Interferon, gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFNA1 (Interferon Alpha 1) • STAT2 (Signal transducer and activator of transcription 2)
    |
    Intron A (interferon α-2b)
    7ms
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=30 --> 12 | Trial primary completion date: Nov 2026 --> Jun 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    10ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=1, Terminated, Roswell Park Cancer Institute | Trial completion date: Apr 2026 --> Jun 2025 | Active, not recruiting --> Terminated; Funding completed
    Trial completion date • Trial termination
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    11ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=1, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=24 --> 1 | Trial completion date: Nov 2027 --> Apr 2026 | Trial primary completion date: Nov 2027 --> Apr 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    12ms
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=30, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    12ms
    E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1673, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Yervoy (ipilimumab) • Intron A (interferon α-2b)